Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Expenditures (2021 - 2024)

SAB Biotherapeutics (SABS) has disclosed Capital Expenditures for 4 consecutive years, with $55377.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures fell 18.4% year-over-year to $55377.0, compared with a TTM value of $337262.0 through Dec 2024, up 71.07%, and an annual FY2025 reading of $933156.0, up 176.69% over the prior year.
  • Capital Expenditures was $55377.0 for Q4 2024 at SAB Biotherapeutics, down from $100300.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.5 million in Q2 2021 and bottomed at $21300.0 in Q1 2023.
  • Average Capital Expenditures over 4 years is $852780.4, with a median of $109027.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures tumbled 98.43% in 2023, then surged 505.98% in 2024.
  • Year by year, Capital Expenditures stood at $2.4 million in 2021, then crashed by 95.01% to $117754.0 in 2022, then tumbled by 42.37% to $67864.0 in 2023, then dropped by 18.4% to $55377.0 in 2024.
  • Business Quant data shows Capital Expenditures for SABS at $55377.0 in Q4 2024, $100300.0 in Q3 2024, and $52511.0 in Q2 2024.